Core Insights - Revenue grew 105% year-over-year to $2.2 million, driven by expanded adoption of the first-generation LungFit PH system across more than 45 hospitals [1] - Customer retention exceeds 90% with over half of the current customer base secured under multiyear agreements, providing a stable foundation for future Gen II conversion [1] - The commercial strategy has shifted toward high-priority hospitals that are likely to adopt Gen I immediately and expand usage once the transport-compatible Gen II system is approved [1] Financial Performance - Operating expenses were reduced by 36% year-over-year, reflecting disciplined cost-cutting in SG&A and the completion of major R&D spending for the Gen II regulatory filing [1] Strategic Moves - The divestiture of the NeuroNOS subsidiary to XTL Biopharmaceuticals allows the company to focus resources on core commercial operations while retaining a 19.9% equity stake and up to $31.5 million in milestones [1] - International expansion reached 40 countries, with management noting a transition from initial device placement to recurring revenue from accessory reorders [1]